The Pharmacologic Treatment of Anxiety and Depression in African Americans: Considerations for the General Practitioner

Tony L. Strickland, Richard Stein, Keh Ming Lin, Emile Risby, Ronald L Fong

Research output: Contribution to journalArticle

21 Scopus citations

Abstract

A growing pool of recent research points to the importance of ethnicity in psychopharmacologic management of depression and anxiety disorders, with sometimes profound implications for efficacy and safety. Such research has provided provocative findings that illustrate important interethnic pharmacogenetic, pharmacokinetic, and pharmacodynamic differences, especially for African Americans. We did a systematic literature review of psychopharmacologic treatment considerations among African Americans with anxiety and mood disturbance seen by primary care physicians, who provide most psychopharmacologic treatment. The findings commonly point to a greater percentage of "poor metabolizers" among African Americans compared with Euro-Americans. General treatment considerations include greater attention to adverse effects and better clinical response and poorer compliance for a given dose, potential need for lower starting doses and slower increases, use of plasma drug levels if available, determination of past responses to a similar drug, and integration of pharmacogenetic information into an overall socioculturally and ethnically sensitive approach to assessment and treatment.

Original languageEnglish (US)
Pages (from-to)371-375
Number of pages5
JournalArchives of Family Medicine
Volume6
Issue number4
StatePublished - Jul 1997
Externally publishedYes

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'The Pharmacologic Treatment of Anxiety and Depression in African Americans: Considerations for the General Practitioner'. Together they form a unique fingerprint.

  • Cite this